ELITE TEST BANK: HAM’S
PRIMARY CARE GERIATRICS
(2026/2027 EDITION)
PART I: THE PRIMER
Mastering geriatric primary care separates elite clinicians from liability risks; applying adult
internal medicine to a failing senescent chassis guarantees iatrogenic harm. This document
installs the S-tier operational logic required to keep your patients alive, functional, and out of the
hospital in the 2026/2027 clinical landscape.
The "Panic Button" Cheat Sheet:
● The 4Ms Framework: Matters Most, Medication, Mentation, Mobility. Interventions that
violate "What Matters Most" are clinically void.
● Beers 2023/2026 Hard Deck: Warfarin is contraindicated as initial VTE/AFib therapy. All
sulfonylureas are banned. Aspirin is void for primary prevention.
● ADA 2026 Frailty Targets: A1c <8.0-8.5% for frail/dementia patients. Deprescribe to
prevent lethal hypoglycemia.
● G2211 Billing Logic: Append to E/M visits (and 2026 home codes 99341-99350) for
longitudinal focal care; invalid with Modifier 25 except for AWVs/vaccines.
● Neurology 2026/2027: Anti-amyloid therapies (donanemab) require strict APOE4
screening and modified titration due to fatal ARIA-E risks.
PART II: THE ELITE TEST BANK
Q1: The 2023/2026 AGS Beers Criteria explicitly reclassified the initiation of
anticoagulation for nonvalvular atrial fibrillation (NVAF) in older adults. What is the
mandated standard of care? A) Initiate Warfarin with a target INR of 2.0-3.0 to ensure tight
reversibility. B) Initiate Rivaroxaban due to once-daily dosing compliance benefits. C) Initiate a
Direct Oral Anticoagulant (DOAC) such as Apixaban, avoiding Warfarin entirely as initial
therapy. D) Initiate dual antiplatelet therapy (Aspirin + Clopidogrel) if the patient has a high fall
risk.
● The Answer: C (Initiate a Direct Oral Anticoagulant (DOAC) such as Apixaban, avoiding
Warfarin entirely as initial therapy.)
● Distractor Analysis: Option A relies on archaic logic; Warfarin has a statistically higher
rate of fatal intracranial hemorrhage. Option B ignores that Rivaroxaban specifically
carries a higher GI bleed risk in the elderly compared to Apixaban. Option D is
malpractice; DAPT is inferior for stroke prevention in NVAF and carries an equal or worse
bleeding profile.
● The Mentor's Analysis: The update is absolute: Warfarin is no longer the starting line.
DOACs demonstrate superior efficacy and lower rates of catastrophic intracranial
bleeding. Professional intuition must default to Apixaban or Edoxaban, adjusting for renal
clearance, relegating Warfarin to mechanical valves or extreme specific contraindications.
,Q2: According to the American Heart Association's 2026 CKM
(Cardiovascular-Kidney-Metabolic) staging, an 68-year-old male with a BMI of 26,
impaired glucose tolerance, but normal blood pressure and eGFR is classified as which
stage? A) Stage 0 B) Stage 1 C) Stage 2 D) Stage 3
● The Answer: B (Stage 1)
● Distractor Analysis: Option A requires normal BMI and normoglycemia. Option C
requires established metabolic risk factors like hypertension, hypertriglyceridemia, or
moderate CKD. Option D indicates subclinical/clinical cardiovascular disease.
● The Mentor's Analysis: CKM Stage 1 is defined by excess or dysfunctional adiposity
(impaired glucose tolerance). Understanding this staging prevents waiting until Stage 2 to
intervene.
CKM Stage Diagnostic Criteria Clinical Focus
Stage 0 Normal BMI, normoglycemia, Primordial prevention
normal BP/lipids
Stage 1 BMI \ge25 (Asian \ge23), Adiposity & lifestyle
impaired glucose tolerance management
Stage 2 HTN, hypertriglyceridemia, Risk factor suppression
CKD
Early aggressive lifestyle modification at Stage 1 prevents the cascading vascular damage that
defines geriatric morbidity.
Q3: When establishing a comprehensive care plan for a severely frail 88-year-old using
the 4Ms framework, what is the mandatory first step before optimizing Medications,
Mentation, or Mobility? A) Conducting a comprehensive medication reconciliation. B)
Performing a Timed Up and Go (TUG) test. C) Determining "What Matters" to the patient. D)
Screening for delirium using the CAM tool.
● The Answer: C (Determining "What Matters" to the patient.)
● Distractor Analysis: Options A, B, and D are critical assessments but are procedurally
subordinate. Optimizing medications without knowing the patient's goals risks prescribing
treatments that extend biological life while destroying their desired quality of life.
● The Mentor's Analysis: Geriatrics focuses on functional autonomy. "What Matters"
dictates the trajectory of the other 3Ms. If a patient's primary goal is to avoid
hospitalization to remain with a spouse, you will aggressively deprescribe and tolerate
higher vital sign targets.
Q4: A practitioner bills the HCPCS G2211 complexity add-on code for a Medicare patient.
Under 2026 CMS regulations, what fundamentally justifies the use of this code? A) The
patient has three or more chronic illnesses requiring specialized monitoring. B) The visit lasted
longer than 45 minutes. C) The practitioner serves as the continuing focal point for the patient's
longitudinal health care needs. D) The practitioner performed a minor procedure on the same
day.
● The Answer: C (The practitioner serves as the continuing focal point for the patient's
longitudinal health care needs.)
● Distractor Analysis: Option A confuses G2211 with Chronic Care Management (CCM)
requirements. Option B refers to prolonged service codes. Option D is a direct violation;
billing G2211 is generally prohibited when an E/M is billed with Modifier 25 for a same-day
minor procedure.
● The Mentor's Analysis: The G2211 code pays for the cognitive load of the relationship,
not the specific disease. Whether treating a sinus infection or heart failure, if you are the
, primary longitudinal quarterback for that patient, the visit is inherently more complex due
to the context of their total care.
Q5: In the context of early Alzheimer's Disease treatment with donanemab (2026 updated
label), what is the primary rationale for utilizing a modified titration dosing schedule? A)
To reduce the gastrointestinal toxicity associated with rapid amyloid clearance. B) To lower the
incidence and severity of Amyloid-Related Imaging Abnormalities (ARIA-E). C) To accommodate
patients with concurrent advanced chronic kidney disease. D) To prevent the rapid onset of
severe bradycardia during infusions.
● The Answer: B (To lower the incidence and severity of Amyloid-Related Imaging
Abnormalities (ARIA-E).)
● Distractor Analysis: Options A, C, and D are fabricated side effects for this specific drug
class. Anti-amyloid monoclonals do not cause primary GI toxicity or bradycardia; their
dose-limiting toxicity is localized brain edema and hemorrhage.
● The Mentor's Analysis: Removing amyloid from brain vascular walls creates
permeability. Rapid removal causes cerebral edema (ARIA-E). The FDA-approved shift to
modified titration smooths this clearance curve, drastically reducing edema risk,
particularly in APOE4 carriers.
Q6: An 82-year-old female presents with the Fried Frailty Phenotype. According to ADA
and NICE guidelines, what is the safest and most appropriate HbA1c target for this
patient? A) < 6.5% B) < 7.0% C) < 7.5% D) < 8.0% to 8.5%
● The Answer: D (< 8.0% to 8.5%)
● Distractor Analysis: Options A, B, and C represent targets for healthy adults. Applying
these to a frail elder requires aggressive insulin or sulfonylurea use, virtually guaranteeing
lethal hypoglycemic events, falls, and subsequent fractures.
● The Mentor's Analysis: The amateur trap is believing high blood sugar kills the elderly
faster than low blood sugar.
Patient Status (Frailty Index) A1c Target (High Hypo Risk) A1c Target (Low Hypo Risk)
Functionally Independent (1-3) 7.1–8.0% \le7.0%
Frail/Dementia (6-8) 7.1–8.5% <8.5%
End of Life (9) Not recommended Not recommended
Severe frailty changes the physics of diabetes management. Tolerate A1c up to 8.5% to
preserve brain perfusion and mechanical stability.
Q7: Which of the following is a hallmark requirement for a hospital to achieve Level 1
Geriatric Emergency Department Accreditation (GEDA) from ACEP in 2026? A)
Fast-tracking all patients over 65 directly to the ICU. B) The integration of over 20 specific
geriatric protocols and dedicated geriatric case managers. C) Mandatory administration of
broad-spectrum antibiotics to all febrile elders in triage. D) Refusal to treat patients who have
advanced directives limiting intubation.
● The Answer: B (The integration of over 20 specific geriatric protocols and dedicated
geriatric case managers.)
● Distractor Analysis: Option A is resource-wasteful and harmful. Option C drives
antimicrobial resistance. Option D is an ethical violation.
● The Mentor's Analysis: The traditional ED is a hostile environment for a senescent
brain. Level 1 GEDs systematically dismantle this hostility by deploying case managers,
structural modifications, and protocol-driven screening (ISAR) to prevent delirium, avoid
hallway placement, and secure safe outpatient transitions.
Q8: Using the SPICES tool to assess an 87-year-old nursing home resident, you note
PRIMARY CARE GERIATRICS
(2026/2027 EDITION)
PART I: THE PRIMER
Mastering geriatric primary care separates elite clinicians from liability risks; applying adult
internal medicine to a failing senescent chassis guarantees iatrogenic harm. This document
installs the S-tier operational logic required to keep your patients alive, functional, and out of the
hospital in the 2026/2027 clinical landscape.
The "Panic Button" Cheat Sheet:
● The 4Ms Framework: Matters Most, Medication, Mentation, Mobility. Interventions that
violate "What Matters Most" are clinically void.
● Beers 2023/2026 Hard Deck: Warfarin is contraindicated as initial VTE/AFib therapy. All
sulfonylureas are banned. Aspirin is void for primary prevention.
● ADA 2026 Frailty Targets: A1c <8.0-8.5% for frail/dementia patients. Deprescribe to
prevent lethal hypoglycemia.
● G2211 Billing Logic: Append to E/M visits (and 2026 home codes 99341-99350) for
longitudinal focal care; invalid with Modifier 25 except for AWVs/vaccines.
● Neurology 2026/2027: Anti-amyloid therapies (donanemab) require strict APOE4
screening and modified titration due to fatal ARIA-E risks.
PART II: THE ELITE TEST BANK
Q1: The 2023/2026 AGS Beers Criteria explicitly reclassified the initiation of
anticoagulation for nonvalvular atrial fibrillation (NVAF) in older adults. What is the
mandated standard of care? A) Initiate Warfarin with a target INR of 2.0-3.0 to ensure tight
reversibility. B) Initiate Rivaroxaban due to once-daily dosing compliance benefits. C) Initiate a
Direct Oral Anticoagulant (DOAC) such as Apixaban, avoiding Warfarin entirely as initial
therapy. D) Initiate dual antiplatelet therapy (Aspirin + Clopidogrel) if the patient has a high fall
risk.
● The Answer: C (Initiate a Direct Oral Anticoagulant (DOAC) such as Apixaban, avoiding
Warfarin entirely as initial therapy.)
● Distractor Analysis: Option A relies on archaic logic; Warfarin has a statistically higher
rate of fatal intracranial hemorrhage. Option B ignores that Rivaroxaban specifically
carries a higher GI bleed risk in the elderly compared to Apixaban. Option D is
malpractice; DAPT is inferior for stroke prevention in NVAF and carries an equal or worse
bleeding profile.
● The Mentor's Analysis: The update is absolute: Warfarin is no longer the starting line.
DOACs demonstrate superior efficacy and lower rates of catastrophic intracranial
bleeding. Professional intuition must default to Apixaban or Edoxaban, adjusting for renal
clearance, relegating Warfarin to mechanical valves or extreme specific contraindications.
,Q2: According to the American Heart Association's 2026 CKM
(Cardiovascular-Kidney-Metabolic) staging, an 68-year-old male with a BMI of 26,
impaired glucose tolerance, but normal blood pressure and eGFR is classified as which
stage? A) Stage 0 B) Stage 1 C) Stage 2 D) Stage 3
● The Answer: B (Stage 1)
● Distractor Analysis: Option A requires normal BMI and normoglycemia. Option C
requires established metabolic risk factors like hypertension, hypertriglyceridemia, or
moderate CKD. Option D indicates subclinical/clinical cardiovascular disease.
● The Mentor's Analysis: CKM Stage 1 is defined by excess or dysfunctional adiposity
(impaired glucose tolerance). Understanding this staging prevents waiting until Stage 2 to
intervene.
CKM Stage Diagnostic Criteria Clinical Focus
Stage 0 Normal BMI, normoglycemia, Primordial prevention
normal BP/lipids
Stage 1 BMI \ge25 (Asian \ge23), Adiposity & lifestyle
impaired glucose tolerance management
Stage 2 HTN, hypertriglyceridemia, Risk factor suppression
CKD
Early aggressive lifestyle modification at Stage 1 prevents the cascading vascular damage that
defines geriatric morbidity.
Q3: When establishing a comprehensive care plan for a severely frail 88-year-old using
the 4Ms framework, what is the mandatory first step before optimizing Medications,
Mentation, or Mobility? A) Conducting a comprehensive medication reconciliation. B)
Performing a Timed Up and Go (TUG) test. C) Determining "What Matters" to the patient. D)
Screening for delirium using the CAM tool.
● The Answer: C (Determining "What Matters" to the patient.)
● Distractor Analysis: Options A, B, and D are critical assessments but are procedurally
subordinate. Optimizing medications without knowing the patient's goals risks prescribing
treatments that extend biological life while destroying their desired quality of life.
● The Mentor's Analysis: Geriatrics focuses on functional autonomy. "What Matters"
dictates the trajectory of the other 3Ms. If a patient's primary goal is to avoid
hospitalization to remain with a spouse, you will aggressively deprescribe and tolerate
higher vital sign targets.
Q4: A practitioner bills the HCPCS G2211 complexity add-on code for a Medicare patient.
Under 2026 CMS regulations, what fundamentally justifies the use of this code? A) The
patient has three or more chronic illnesses requiring specialized monitoring. B) The visit lasted
longer than 45 minutes. C) The practitioner serves as the continuing focal point for the patient's
longitudinal health care needs. D) The practitioner performed a minor procedure on the same
day.
● The Answer: C (The practitioner serves as the continuing focal point for the patient's
longitudinal health care needs.)
● Distractor Analysis: Option A confuses G2211 with Chronic Care Management (CCM)
requirements. Option B refers to prolonged service codes. Option D is a direct violation;
billing G2211 is generally prohibited when an E/M is billed with Modifier 25 for a same-day
minor procedure.
● The Mentor's Analysis: The G2211 code pays for the cognitive load of the relationship,
not the specific disease. Whether treating a sinus infection or heart failure, if you are the
, primary longitudinal quarterback for that patient, the visit is inherently more complex due
to the context of their total care.
Q5: In the context of early Alzheimer's Disease treatment with donanemab (2026 updated
label), what is the primary rationale for utilizing a modified titration dosing schedule? A)
To reduce the gastrointestinal toxicity associated with rapid amyloid clearance. B) To lower the
incidence and severity of Amyloid-Related Imaging Abnormalities (ARIA-E). C) To accommodate
patients with concurrent advanced chronic kidney disease. D) To prevent the rapid onset of
severe bradycardia during infusions.
● The Answer: B (To lower the incidence and severity of Amyloid-Related Imaging
Abnormalities (ARIA-E).)
● Distractor Analysis: Options A, C, and D are fabricated side effects for this specific drug
class. Anti-amyloid monoclonals do not cause primary GI toxicity or bradycardia; their
dose-limiting toxicity is localized brain edema and hemorrhage.
● The Mentor's Analysis: Removing amyloid from brain vascular walls creates
permeability. Rapid removal causes cerebral edema (ARIA-E). The FDA-approved shift to
modified titration smooths this clearance curve, drastically reducing edema risk,
particularly in APOE4 carriers.
Q6: An 82-year-old female presents with the Fried Frailty Phenotype. According to ADA
and NICE guidelines, what is the safest and most appropriate HbA1c target for this
patient? A) < 6.5% B) < 7.0% C) < 7.5% D) < 8.0% to 8.5%
● The Answer: D (< 8.0% to 8.5%)
● Distractor Analysis: Options A, B, and C represent targets for healthy adults. Applying
these to a frail elder requires aggressive insulin or sulfonylurea use, virtually guaranteeing
lethal hypoglycemic events, falls, and subsequent fractures.
● The Mentor's Analysis: The amateur trap is believing high blood sugar kills the elderly
faster than low blood sugar.
Patient Status (Frailty Index) A1c Target (High Hypo Risk) A1c Target (Low Hypo Risk)
Functionally Independent (1-3) 7.1–8.0% \le7.0%
Frail/Dementia (6-8) 7.1–8.5% <8.5%
End of Life (9) Not recommended Not recommended
Severe frailty changes the physics of diabetes management. Tolerate A1c up to 8.5% to
preserve brain perfusion and mechanical stability.
Q7: Which of the following is a hallmark requirement for a hospital to achieve Level 1
Geriatric Emergency Department Accreditation (GEDA) from ACEP in 2026? A)
Fast-tracking all patients over 65 directly to the ICU. B) The integration of over 20 specific
geriatric protocols and dedicated geriatric case managers. C) Mandatory administration of
broad-spectrum antibiotics to all febrile elders in triage. D) Refusal to treat patients who have
advanced directives limiting intubation.
● The Answer: B (The integration of over 20 specific geriatric protocols and dedicated
geriatric case managers.)
● Distractor Analysis: Option A is resource-wasteful and harmful. Option C drives
antimicrobial resistance. Option D is an ethical violation.
● The Mentor's Analysis: The traditional ED is a hostile environment for a senescent
brain. Level 1 GEDs systematically dismantle this hostility by deploying case managers,
structural modifications, and protocol-driven screening (ISAR) to prevent delirium, avoid
hallway placement, and secure safe outpatient transitions.
Q8: Using the SPICES tool to assess an 87-year-old nursing home resident, you note
